The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain.
about
BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteinsA novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase geneThe p65 subunit is responsible for the strong transcription activating potential of NF-kappa BThe NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa BBoth N- and C-terminal domains of RelB are required for full transactivation: role of the N-terminal leucine zipper-like motifPurification, reconstitution, and I kappa B association of the c-Rel-p65 (RelA) complex, a strong activator of transcriptionRegulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factorsRegulation of human immunodeficiency virus enhancer function by PRDII-BF1 and c-rel gene productsThe conserved redox-sensitive cysteine residue of the DNA-binding region in the c-Rel protein is involved in the regulation of the phosphorylation of the proteinNF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responsesThe c-rel protooncogene product c-Rel but not NF-kappa B binds to the intronic region of the human interferon-gamma gene at a site related to an interferon-stimulable response elementCytoplasmic activation of GAF, an IFN-gamma-regulated DNA-binding factorNF-kappa B subunit-specific regulation of the interleukin-8 promoterMembers of the nuclear factor kappa B family transactivate the murine c-myb gene.A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation.In vivo control of NF-kappa B activation by I kappa B alpha.Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62.Molecular cloning of cDNA encoding the Xenopus homolog of mammalian RelB.Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiationRole of cysteine62 in DNA recognition by the P50 subunit of NF-kappa BAbsence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethalityThe C terminus of the NF-kappa B p50 precursor and an I kappa B isoform contain transcription activation domains.Kinetic perspectives of T cell antigen receptor signaling. A two-tier model for T cell full activation.Alternative splicing of RNA transcripts encoded by the murine p105 NF-kappa B gene generates I kappa B gamma isoforms with different inhibitory activities.A DNA binding domain is contained in the C-terminus of wild type p53 proteinThe relocalization of v-Rel from the nucleus to the cytoplasm coincides with induction of expression of Ikba and nfkb1 and stabilization of I kappa B-alpha.IKK biology.Chronic human immunodeficiency virus type 1 infection of myeloid cells disrupts the autoregulatory control of the NF-kappaB/Rel pathway via enhanced IkappaBalpha degradationInhibition of transcription factors belonging to the rel/NF-kappa B family by a transdominant negative mutantThe c-rel protooncogene product represses NF-kappa B p65-mediated transcriptional activation of the long terminal repeat of type 1 human immunodeficiency virus.Activation of NF-kappaB/Rel by CD40 engagement induces the mouse germ line immunoglobulin Cgamma1 promoter.Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformationTransformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids.In vivo evolution of c-rel oncogenic potential.Mutational analysis of the p50 subunit of NF-kappa B and inhibition of NF-kappa B activity by trans-dominant p50 mutants.An interaction between the DNA-binding domains of RelA(p65) and Sp1 mediates human immunodeficiency virus gene activationAlternate RNA splicing of murine nfkb1 generates a nuclear isoform of the p50 precursor NF-kappa B1 that can function as a transactivator of NF-kappa B-regulated transcription.Differential pp40I kappa B-beta inhibition of DNA binding by rel proteinsThe p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription.vRel is an inactive member of the Rel family of transcriptional activating proteins.
P2860
Q24315909-3BED642F-AAEE-49E3-895C-A1FDD8C75AC7Q24555708-079FFD19-BF7D-4DB3-9A29-EB66C77D1A3AQ24564667-A1D35F3E-88DC-4DBE-8783-E7C423B20C97Q24564833-F8573F9F-4559-4B9B-9940-69D69DDCC757Q24606830-EE93CD7A-05D5-4E62-8EBE-0339C1752F18Q24613327-5F28681C-EF9E-41C7-8A49-AF01A76FEC20Q24651506-33FDDEA0-4FA9-4A93-AF71-4AFD350465E9Q24655654-2D8A6DED-6CED-4C20-B13F-19AF6FFE4D5AQ28344966-2C47BDD4-52C7-4BBE-B99D-CB7D3EA8A435Q28505819-D62A27AD-0220-404E-B03F-F48231C4945EQ28645819-37DD813F-ED34-47D2-9308-BD778DD2606EQ28646302-983E6999-B081-4FEB-A15A-E9A395CD0DBBQ28646361-0CEE041C-060C-4B30-B5CA-9E9F9C338F74Q30464811-663B408A-4CA9-4857-AB16-9C3306FA77BEQ34059393-2A18C031-4032-447E-89B2-872084CC87F4Q34069959-AD8C7F47-B345-4807-952C-FF06252A915FQ34313863-307F3C2B-E9C2-4406-8BEE-1828410A94ADQ34781115-00556BAF-B7B1-4DD0-BB00-3628C00B602DQ34796730-45B8B411-3488-494F-B39B-E0AF0858E2ABQ34979723-61EA7161-1873-4434-9A34-C2DD8D4F9F85Q35064315-C36A7E16-58AC-40E6-967F-E6E076FE1F6EQ35069893-F5D6AA24-D7B8-42D1-A176-B5C4E3406129Q35076704-16C7B839-20E0-438E-94DB-EF2BD84218D6Q35230057-FF619622-F3E3-4152-83AF-F771896BCFE8Q35785411-4B4BA895-B120-4973-B7C6-27B0CCC83C7AQ35829918-EFD44C88-9AA9-4410-B1D9-162CFB67D838Q35848596-9BA1D701-A1FB-4935-973B-0FA39571CE3DQ35865967-AE2F183B-94EC-43D6-91AC-9DFE5169D0C5Q35926996-54D61450-9324-463C-82FF-63D24F1D25F0Q36086609-5024F618-98FE-48E6-B9B4-3B6D16121FC5Q36561776-897E3B88-A19F-4540-8E9B-FD945E8589F0Q36630907-BA1DE708-32F8-48DB-BE90-A3D5CE316452Q36631040-CC293B3B-6E2E-4269-9D4B-1CDC191C0D90Q36631973-9BA6D9BF-7EC2-4055-9BB7-3B0E1DBBEEBBQ36639395-BB94C3D3-8C4E-4ABF-9FB5-B34892B680FEQ36666995-85420950-AE04-45A3-B8E8-808ABD1B4085Q36673048-CA0B52BA-5F79-435A-9276-67B4BC2082D9Q36676544-E67509BC-AAD3-4150-B9CA-FFA4302734F2Q36685220-6668A739-AEA9-4C3C-9625-C72EF26B6786Q36694853-33B10B12-5200-4539-8231-1A33859F5F0C
P2860
The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
The mouse c-rel protein has an ...... tional transactivation domain.
@ast
The mouse c-rel protein has an ...... tional transactivation domain.
@en
type
label
The mouse c-rel protein has an ...... tional transactivation domain.
@ast
The mouse c-rel protein has an ...... tional transactivation domain.
@en
prefLabel
The mouse c-rel protein has an ...... tional transactivation domain.
@ast
The mouse c-rel protein has an ...... tional transactivation domain.
@en
P2093
P2860
P356
P1476
The mouse c-rel protein has an ...... tional transactivation domain.
@en
P2093
P2860
P304
P356
10.1128/MCB.10.10.5473
P407
P577
1990-10-01T00:00:00Z